The size of the Asia Pacific Clostridium Botulinum Market is predicted to be growing at a healthy rate during the forecast period.
Government support from the Asia Pacific countries in setting up healthcare infrastructures like hospitals and clinics is expected to add fuel to the market growth in this region. Adopting new non-surgical aesthetic methods, lack of cleanliness, surging number of expertise professionals performing non-surgical botulinum toxin procedures, tax advantages, and colossal government support in setting up healthcare infrastructures like hospitals research clinics are fueling the market growth over the period. Nearly 1,801,033 procedures were performed with botulinum toxin, and out of the total, 1,638,940 were females, according to the American Society for Aesthetic Plastic Surgery in 2018. FDA approvals for botulinum treatments, growing awareness, and increasing cosmetic and therapeutic procedures across the region influence market growth.
The pressuring prices related to research and development projects and the government's sternness are some obstacles that hinder market growth in the APAC region.
This market research report on the Asia Pacific Clostridium Botulinum Market has been segmented & sub-segmented into the following categories:
APAC is anticipated to showcase the highest growth rate with the highest share and is likely to grow in the forthcoming years. Factors like aging demographics, increasing discretionary expenses, which give outcome in the growing demand for anti-aging products. Also, rising social awareness concerning the commercial availability of products in the APAC region.
Countries like India and China are contributing a significant share of the clostridium botulinum market of this region. Factors like large population, common bacterial diseases, and favorable reimbursement policies for treatments and therapies propel this region's market growth.
The Indian market is expected to have notable growth in the market due to the growing demand for aesthetic procedures, particularly botulinum toxin. The old age people population, augmenting the number of surgeons, and the rise in facial aesthetic procedures add fuel to the Clostridium botulinum market growth during the analysis period.
The Japanese market is expected to have considerable growth in the upcoming years due to the substitution of non-surgical procedures and escalating healthcare expenses in appearing markets. In China, facial neuropathy is increasing by around 0.003%, which is commonly seen in women. Moreover, escalating research and development practices and obtaining efficacy solutions for botulism promote the region's clostridium market growth.
Some of the top players operating in the Asia Pacific clostridium botulinum infection market are XOMA Ltd., AlphaVax, Inc., Cangene Corporation, Morphotek, Inc., DynPort Vaccine Company LLC, Emergent BioSolutions, Inc., Molecular Targeting Technologies, Inc., and many others.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Botulinum toxin type A
5.1.3 Botulinum toxin type B
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2.4 Y-o-Y Growth Analysis, By application
5.2.5 Market Attractiveness Analysis, By application
5.2.6 Market Share Analysis, By application
5.3 Distribution channel
5.3.4 Retail pharmacies
5.3.5 Y-o-Y Growth Analysis, By distribution channel
5.3.6 Market Attractiveness Analysis, By distribution channel
5.3.7 Market Share Analysis, By distribution channel
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Product
184.108.40.206 By application
220.127.116.11 By distribution channel
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product
126.96.36.199 By application
188.8.131.52 By distribution channel
6.1.5 Market Share Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Product
18.104.22.168 By application
22.214.171.124 By distribution channel
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 DynPort Vaccine Company
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Emergent BioSolutions, Inc.
8.3 XOMA Ltd.
8.5 Cangene Corporation
8.6 Morphotek, Inc.
8.7 Morphotek, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures